Welcome to our dedicated page for Integra Lifesciences Hldgs Cp SEC filings (Ticker: IART), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Integra LifeSciences Holdings Corporation (IART) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Integra’s Form 8-K filings and related exhibits offer insight into its financial reporting practices, governance programs, and key operational updates as a global medical technology company focused on neurosurgery and tissue reconstruction.
Recent Form 8-K filings include results of operations and financial condition for specific quarters, where Integra furnishes press releases detailing revenues, segment performance for Codman Specialty Surgical and Tissue Technologies, and reconciliations between GAAP and non-GAAP measures. These filings explain how management uses metrics such as organic revenues, adjusted EBITDA, adjusted net income, adjusted gross margin, adjusted earnings per diluted share, net debt, free cash flow, and adjusted free cash flow conversion to evaluate performance and compare results over time.
Other 8-K filings address governance and executive programs, such as a change in control severance program for certain executives. That program, as described in the filing, outlines severance payments, bonus treatment, COBRA premium subsidies, outplacement services, and potential adjustments for excise tax exposure in connection with qualifying terminations following a change in control, with a defined term and renewal provisions overseen by the Board’s Compensation Committee.
Through this filings page, users can review how Integra discusses topics such as quality and compliance initiatives, manufacturing transitions, and the financial impact of structural optimization, acquisition and divestiture-related charges, EU Medical Device Regulation costs, recall-related charges, and impairment charges. Stock Titan enhances access to these documents with AI-powered summaries that help explain technical sections of 10-Ks, 10-Qs, and 8-Ks, highlight key adjustments and definitions, and surface important trends without replacing the underlying filings.
Filings are updated in near real time from the SEC’s EDGAR system, and users can also monitor items related to executive compensation structures and other governance matters. For investors analyzing IART, this page serves as a focused entry point into Integra’s official regulatory record, with tools to interpret complex disclosures more efficiently.
Integra LifeSciences (IART) reported an insider equity event. EVP & President, International Harvinder Singh vested 11,965 restricted stock units on 10/12/2025, which settled into common stock. To cover taxes, 3,281 shares were withheld at $13.34, and the reporting person retained 8,684 shares from the vesting. Following these transactions, direct beneficial ownership stood at 21,936 common shares.
The RSU award vested in full on the third anniversary of its grant date (10/12/2022). Derivative securities beneficially owned following the event were 22,566 RSUs.
Chantal Veillon-Berteloot, EVP & CHRO of Integra LifeSciences Holdings Corp (IART), reported two sales of company common stock on 09/01/2025. The filing shows a disposition of 2,139 shares at $15.13, leaving 29,059 shares beneficially owned after that transaction, and a separate disposition of 1,412 shares at $15.13, leaving 27,647 shares beneficially owned after that transaction.
The Form 4 is signed by an attorney-in-fact and includes a Power of Attorney exhibit; it documents insider selling and fulfills disclosure requirements under Section 16.
Integra LifeSciences (IART) Form 4: Director Stuart Essig reported multiple internal transfers of common stock in August 2025. On August 14, 2025 he transferred 200,000 shares to a grantor trust for which his spouse is trustee and received assets of equal fair market value. The same date shows a 200,000-share acquisition entry at $13.62 and a 200,000-share disposition at $13.62 reflecting the trust transfer. Prior to that, on August 8, 2025, 180,080 shares were distributed to Essig from GRAT E as an annuity payment and 500,000 shares were distributed from GRAT F as an annuity payment; GRAT F was then terminated because remaining shares were insufficient to satisfy the annuity obligation. Following the reported transactions, the filings list 1,152,236 shares beneficially owned directly and various indirect holdings through trusts (including 219,920 by GRAT E and 213,115 by a family trust).